介入化疗栓塞联合免疫综合治疗在晚期肾癌中的短期效果及预后观察  

Short-termEffect and Prognosis of Interventional Chemoembolization Combined with Immunotherapy in the Treatment of Advanced Renal Cancer

作　　者：仝世义 Tong Shiyi(Department of Intervention Section,Sanmenxia Central Hospital Affiliated to Henan Universityof Science and Technology,Sanmenxia 472000)

机构地区：[1]河南科技大学附属三门峡市中心医院介入科

出　　处：《数理医药学杂志》2019年第6期845-846,共2页Journal of Mathematical Medicine

摘　　要：目的:探讨介入化疗栓塞联合免疫综合治疗在晚期肾癌中的短期效果及预后。方法:在医院2015年12月~2017年1月期间诊治的晚期肾癌患者中选取84例作研究对象,并按治疗方案不同予以分组。对照组(n=42)单纯采取动脉栓塞技术,研究组(n=42)则应用介入化疗栓塞联合免疫应答治疗,就两组患者短期治疗效果以及预后指标差异进行统计学分析。结果:研究组患者近期治疗有效率是78.57%,高于对照组的57.14%(P<0.05);研究组患者治疗1年后生存率是80.95%,高于对照组的59.52%(P<0.05)。结论:介入化疗栓塞联合免疫综合治疗在晚期肾癌中的短期效果确切,并能改善患者预后,值得借鉴。Objective: To explore the short-term effect and prognosis of interventional chemoembolization combined with integrated immunotherapy in advanced renal cancer. Methods: 84 cases of patients with advanced renal cancer treated in a hospital from December 2015 and January 2017 were selected as the research object, and divided into control group (arterial embolization alone) and observation group (interventional chemoembolization combined with immunotherapy) according to the different treatment methods,with 42 cases in each group. The effect of short-term treatment and the difference of prognosis index of the two groups were analyzed statistically. Results: The short-term effective rate of the patients in the study group was 78.57%, which was higher than that in the control group (57.14%, P < 0.05). The survival rate was 80.95% in the study group after one year treatment, which was higher than 59.52% in the control group ( P < 0.05). Conclusion: The short-term effect of interventional chemoembolization combined with immunotherapy in advanced renal cancer is effective and can improve the prognosis of the patients, which is worthy of reference.

关 键 词：介入化疗栓塞 动脉栓塞技术 免疫综合疗法 

分 类 号：R737.11[医药卫生—肿瘤]